Capelight Capital Asset Management LP Purchases 50,000 Shares of Tempus AI, Inc. $TEM

Key Points

• Capelight Capital Asset Management acquired 50,000 Tempus AI shares valued at approximately $4.1 million, making up 1.6% of its portfolio. Institutional investors collectively own 24.22% of the company.
• Analyst sentiment is mixed but leans supportive: 11 analysts rate Tempus AI a Buy, nine Hold, and two Sell. The stock has an average rating of Hold and an average price target of $72.37.
• Tempus AI reported quarterly revenue of $382.5 million, up 21.6% year over year, and a narrower-than-expected loss of $0.04 per share. However, insiders sold roughly 1.28 million shares worth $80.4 million over the past 90 days, while the company remains unprofitable and highly volatile.

Capelight Capital Asset Management LP acquired a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $4,095,000. Tempus AI comprises 1.6% of Capelight Capital Asset Management LP's holdings, making the stock its 21st largest position.

Other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. grew its position in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock valued at $195,549,000 after acquiring an additional 821,490 shares during the period. Eagle Health Investments LP acquired a new stake in shares of Tempus AI during the 1st quarter valued at about $11,588,000. Aristotle Atlantic Partners LLC acquired a new stake in shares of Tempus AI during the 1st quarter valued at about $6,179,000. Finally, Fagan Associates Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $5,265,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TEM. Lake Street Capital downgraded Tempus AI to a "hold" rating in a research report on Monday, July 20th. JPMorgan Chase & Co. boosted their price objective on Tempus AI from $45.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, October 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday. Freedom Capital raised Tempus AI to a "hold" rating in a research note on Tuesday, June 30th. Finally, Canaccord Genuity Group increased their target price on Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, October 12th. Eleven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Tempus AI presently has an average rating of "Hold" and an average target price of $72.37.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 2,951 shares of the firm's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the sale, the executive vice president owned 135,189 shares of the company's stock, valued at $10,139,175. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of Tempus AI stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the sale, the chief accounting officer owned 60,804 shares in the company, valued at $4,560,300. This represents a 10.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,280,965 shares of company stock valued at $80,397,564 over the last 90 days. Corporate insiders own 24.26% of the company's stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

Tempus AI Trading Down 0.0%

Shares of Tempus AI stock opened at $67.61 on Monday. The stock has a market cap of $12.20 billion, a P/E ratio of -46.95 and a beta of 3.54. The stock's 50 day simple moving average is $69.24 and its 200-day simple moving average is $57.26. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $93.38. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period in the previous year, the firm earned ($0.22) earnings per share. Tempus AI's quarterly revenue was up 21.6% compared to the same quarter last year. Analysts predict that Tempus AI, Inc. will post -1.43 EPS for the current fiscal year.

Tempus AI Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.